Natixis Advisors, L.P. Astrazeneca PLC Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Astrazeneca PLC stock. As of the latest transaction made, Natixis Advisors, L.P. holds 1,837,925 shares of AZN stock, worth $158 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
1,837,925
Previous 2,236,011
17.8%
Holding current value
$158 Million
Previous $164 Million
21.85%
% of portfolio
0.2%
Previous 0.3%
Shares
32 transactions
Others Institutions Holding AZN
# of Institutions
1,412Shares Held
496MCall Options Held
7.11MPut Options Held
2.56M-
Price T Rowe Associates Inc Baltimore, MD51.9MShares$4.46 Billion0.41% of portfolio
-
Primecap Management CO Pasadena, CA41.2MShares$3.54 Billion2.35% of portfolio
-
Wellington Management Group LLP Boston, MA34.3MShares$2.95 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA31.4MShares$2.7 Billion0.39% of portfolio
-
Bank Of America Corp Charlotte, NC31.2MShares$2.68 Billion0.16% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $266B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...